Disc Medicine, Inc.
$70.35
-2.3%Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -11.7).
Valuation inputs: P/E -11.7, earnings yield N/A, momentum -2.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -28.7%, ROIC -30.6%).
Profitability stack: net margin 0.0%, ROE -28.7%, ROIC -30.6%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +8.3%, momentum -2.3%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Disc Medicine, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Disc Medicine, Inc. Fair Value Envelope
No Revenue Data
IRON has not reported any revenue values in the available annual periods.
Disc Medicine, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
IRON has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
IRON has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
IRON has not reported any net profit margin values in the available annual periods.
Disc Medicine, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Disc Medicine, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Disc Medicine, Inc. Street Expectations Map
Wall Street analysts project that IRON stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 103.33, with estimates ranging from a low of 80.00 to a high of 125.00.
The consensus 1-year price target stands at 103.33, with estimates ranging from a low of 80.00 to a high of 125.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Disc Medicine, Inc. Insider Positioning
During the last 12 months, insiders have sold $73.24M worth of IRON shares, with no buying activity reported.
3 Months
0
0.00
3.5K
233.47K
-233K
-$233K
3-6 Months
0
0.00
60.9K
4.42M
-4.4M
-$4.42M
6-9 Months
0
0.00
776.5K
62.34M
-62.3M
-$62.34M
9-12 Months
0
0.00
104.0K
6.24M
-6.2M
-$6.24M
Top Buyers
No buying activity
Top Sellers
Ai Dmi Llc
10 Percent Owner
$59.87M
Bitterman Kevin
Director
$8.59M
Quisel John D
Director, Officer: Chief Executive Officer
$1.54M
Yu Jonathan Yen-Wen
Officer: Chief Operating Officer
$894K
Savage William Jacob
Officer: Chief Medical Officer
$876K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $73.24M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
IRON has not reported any dividend yield values in the available annual periods.
iron Dividend History
Learning Layer
Related Guides
Build conviction on IRON by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.